Waltham, Mass., August 10, 2026

Spyre Therapeutics, Inc. announced the launch of its SPY772 combination program and initiation of the randomized Phase 2 SKYLIGHT trial evaluating dual inhibition of TL1A and IL-17A/F in patients with hidradenitis suppurativa (HS). The SPY772 program combines SPY072, a long-acting anti-TL1A antibody, with SPY007, a novel long-acting anti-IL-17A/F antibody in preclinical development. The program is designed to potentially deliver improved efficacy, durability and dosing convenience for patients with moderate-to-severe HS, a chronic inflammatory skin disease associated with painful lesions and significant quality-of-life impacts

Spyre Launches SPY772 Dual-Target Program

The SPY772 program is based on the hypothesis that simultaneously targeting complementary inflammatory pathways could improve disease control compared with single-target approaches. The program combines inhibition of TL1A and IL-17A/F, two validated inflammatory pathways involved in immune-mediated diseases. SPY072 is a long-acting anti-TL1A antibody, while SPY007 is a long-acting anti-IL-17A/F antibody currently in preclinical development. Spyre is developing the combination as a potential long-acting coformulation designed to simplify treatment while maintaining sustained pathway inhibition. The company believes this strategy could potentially raise the efficacy ceiling in HS and other inflammatory diseases with significant unmet medical needs.

Phase 2 SKYLIGHT Trial Begins in Hidradenitis Suppurativa

The SKYLIGHT Phase 2 trial is a randomized, placebo-controlled proof-of-concept study designed to evaluate whether adding SPY072 to bimekizumab, an anti-IL-17A/F therapy, can improve clinical outcomes compared with bimekizumab alone. The study is expected to enroll approximately 150 adults with moderate-to-severe hidradenitis suppurativa. Participants will receive background bimekizumab therapy together with either SPY072 or placebo. The primary endpoint is the proportion of patients achieving a HiSCR75 response at Week 16, a measure of substantial reduction in HS inflammatory lesions. Site activation has begun, with topline Week 16 results expected in late 2027 or early 2028.

Advertisement

cGxPJobs Banner

Dual Inhibition Could Expand Treatment Options for HS

Hidradenitis suppurativa is a chronic inflammatory skin disease in which many patients do not achieve adequate disease control with currently available therapies. Spyre is evaluating whether simultaneous targeting of TL1A and IL-17A/F can produce greater efficacy than inhibition of either pathway alone. The company expects the SKYLIGHT study to provide an early clinical assessment of this dual-target strategy. If the study generates positive proof-of-concept data, the results could support further development of the long-acting SPY772 combination and potentially enable exploration in additional inflammatory diseases.

Spyre Expands Long-Acting Immunology Pipeline

The SPY772 program expands Spyre Therapeutics’ pipeline of extended half-life antibody programs targeting important inflammatory pathways. The company’s broader pipeline includes investigational antibodies against α4β7, TL1A, IL-23 and IL-17A/F, as well as rational combination programs. Through long-acting antibody approaches, Spyre aims to improve treatment durability and simplify administration while pursuing more complete disease control. The SKYLIGHT study represents an important clinical test of the company’s strategy to combine complementary mechanisms in immunology and could help determine whether dual pathway inhibition offers meaningful benefits for patients with HS.

Source: Spyre Therapeutics press release